KYMR - NASDAQ
Kymera Therapeutics, Inc.
$73.21
+0.72%Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
At a Glance
Live SnapshotKymera Therapeutics, Inc. Management Team
Mr. Noah Goodman M.B.A.
Chief Business Officer
Mr. Bruce N. Jacobs CFA
Chief Financial Officer
Compensation
$754,540
Mr. Brian R. Adams J.D.
Chief Legal Officer & Corporate Secretary
Ms. Ellen V. Chiniara Esq., J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$696,080
Dr. Jared A. Gollob M.D.
Chief Medical Officer
Compensation
$768,400
Dr. Jeremy G. Chadwick Ph.D.
Chief Operating Officer
Compensation
$719,400
Dr. Bruce L. Booth DPHIL, Ph.D.
Co-Founder & Independent Chairman
Compensation
$70,000
Dr. Nello Mainolfi M.D., Ph.D.
Co-Founder, President, Chief Executive Officer & Director
Compensation
$1,226,500
Ms. Karen Weisbach
Head of People & Culture
Dr. Juliet Williams B.A Ph.D.
Head of Research
Ms. Justine E. Koenigsberg
Vice President of Investor Relations
Kymera Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $163.14M and sold $21.77M worth of KYMR shares, resulting in $141.36M of net buying activity.
3 Months
0
0.00
83.8K
6.90M
-6.9M
-$6.90M
3-6 Months
1.8M
158.12M
95.3K
8.10M
+150.0M
+$150.02M
6-9 Months
0
0.00
127.4K
6.54M
-6.5M
-$6.54M
9-12 Months
114.0K
5.01M
4.5K
225.00K
+4.8M
+$4.79M
Top Buyers
Baker Bros. Advisors Lp
Director, 10 Percent Owner:
$160.55M
Bvf Partners L P/Il
Director, Other: See Remarks And Footnotes
$2.59M
Top Sellers
Mainolfi Nello
Director, Officer: Chief Executive Officer
$6.71M
Chadwick Jeremy G
Officer: Chief Operating Officer
$4.63M
Jacobs Bruce N.
Officer: Chief Financial Officer
$3.96M
Booth Bruce
Director
$3.04M
Esposito Pamela
Director
$1.43M
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $141.36M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
KYMR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 18, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 16, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.